^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DOT1L mutation

    i
    Other names: DOT1L, DOT1 Like Histone Lysine Methyltransferase, KMT4, Histone-Lysine N-Methyltransferase, H3 Lysine-79 Specific, Histone H3-K79 Methyltransferase, Histone Methyltransferase DOT1L, Lysine N-Methyltransferase 4, DOT1-Like Protein, H3-K79-HMTase, DOT1-Like, Histone H3 Methyltransferase (S. Cerevisiae), DOT1 Like Histone H3K79 Methyltransferase, DOT1-Like, Histone H3 Methyltransferase, DOT1-Like Histone Methyltransferase
    Entrez ID:
    84444
    Related biomarkers:
    Expression
    over2years
    DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer (IASLC-WCLC 2023)
    Our findings suggest that baseline mutations in the uncommon gene DOT1L are associated with higher levels of TMB and chromosomal instability. These mutations could be a potential biomarker for identifying patients with locally advanced NSCLC who may benefit from ICI treatments.
    Clinical • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • DOT1L (DOT1 Like Histone Lysine Methyltransferase)
    |
    PD-L1 expression • TP53 mutation • EGFR mutation • EGFR exon 19 deletion • DOT1L mutation